Bridging the Gap Between Immunotherapy & Hypofractionated Radiation Therapy
June 17, 2016
Hilton Orlando • Orlando, Florida
Presented by the the Radiosurgery Society (RSS) in collaboration with the Society for Immunotherapy of Cancer (SITC), the Radiation Research Society (RRS), and the National Cancer Institute (NCI)
This joint symposium was part of the Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy (SRS/SBRT) Scientific Meeting 2016 - Bridging the Gap: Advancing Research and Education on June 16-18, 2016. This meeting provided an opportunity for knowledge exchange and collaboration among all SRS/SBRT healthcare providers, including radiation oncologists, neurosurgeons, surgeons, oncologists, medical physicists, and industry leaders.
"Bridging the Gap Between Immunotherapy & Hypofractionated Radiation Therapy" addressed how radiation can enhance immune responses to tumors and how other novel delivery options may affect immune responses. This symposium covered (1) the impact of radiation dose on immune modulation (so-called “abscopal effects”); (2) the impact of sequencing for radiation therapy combined with immunotherapy; and (3) the appropriateness of biomarker selection in assessing the efficacy of clinical trials combined with radiation therapy and immunotherapy. Clinicians and researchers with an interest in radiotherapy and/or immunology had an opportunity to open a dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy.
Moderators
Mansoor M. Ahmed, PhD – National Cancer Institute
Samir N. Khleif, MD – Georgia Regents University, SITC Board Director
Symposium Topics
Opening Remarks: Beyond Radiosurgery
The RSS’ Mission to Push the Boundaries of Hypo-Fractionated Radiation
Anand Mahadevan, MD – Beth Israel Deaconess Medical Center
NCI's Mission and Its Role in Promoting the Science of Radiation in Immunology
Mansoor M. Ahmed, PhD – National Cancer Institute
SITC’s Mission and Its Role in Promoting Cancer Immunotherapy Among Radiation Oncologists and Radiation Biologists
Samir N. Khleif, MD – Georgia Regents University, SITC Board Director
RRS' Mission and Its Role in Promoting the Importance of Radiation Biology in Cancer Immunology
Charlie L. Limoli, PhD – University of California Irvine Cancer Research Institute, RRS President
Overview of Cancer Immunology and Immunotherapy
Samir N. Khleif, MD – Georgia Regents University, SITC Board Director
Importance of Radiation Doses for Immune Modulation and Sequencing for Immunotherapy Synergy in Solid Tumors
Marka R. Crittenden, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center
Current State of Clinical Trials Combining Radiation and Immunotherapy: Challenges and Opportunities
Andy J. Minn, MD, PhD – University of Pennsylvania
Translational Science and Biomarkers Selection for Monitoring Efficacy of Trials Combining Radiation Plus Immunotherapy
Arta Monjazeb, MD, PhD – University of California Davis Comprehensive Cancer Center
The Showdown Debate: May the Force Be With You
Debate Topic: Ablative Vs. Nonablative Radiation for Abscopal Effects
Silvia C. Formenti, MD – Weill Cornell Medical College, Cornell University
Chandan Guha, MB, BS, PhD – Albert Einstein College of Medicine, Montefiore Medical Center
Get more information here.